财务表现 - 公司2024年初步未经审计的总净收入约为8800万美元，符合之前公布的8700万至9500万美元的预期范围[4] - 公司预计2024年运营费用在1.15亿至1.2亿美元之间，符合之前公布的预期范围[4] - 截至2024年12月31日，公司初步未经审计的现金及现金等价物约为6700万美元，2024财年的总现金投资约为1100万美元，低于之前公布的1500万至2000万美元的预期范围[4] 业务重组 - 公司计划通过业务重组优化运营，预计将裁员约13%，并产生高达260万美元的重组费用，主要包括210万美元的现金相关通知和遣散费以及50万美元的股票补偿加速[9][10][11] - 公司业务重组将分为两个业务单元，一个专注于DANYELZA的市场扩展和naxitamab的临床及商业开发，另一个专注于放射性药物平台，包括SADA PRIT技术平台和早期研发管线[8] - 公司预计重组费用将影响2024年第四季度和2025年第一季度的运营结果，现金支付将持续到2026年上半年[11] - 公司预计2024年第四季度和2025年第一季度将记录与业务重组相关的费用[11] - 公司预计2024年第四季度和2025年第一季度将记录与业务重组相关的费用[11] 人事变动 - 公司高级副总裁兼首席商务官Susan Smith将于2025年4月9日离职[12] - 公司任命Doug Gentilcore为DANYELZA业务单元负责人，Natalie Tucker为放射性药物业务负责人[13]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 10, 2025 NeuroOne Medical Technologies Corporation (Exact name of registrant as specified in its charter) Delaware 001-40439 27-0863354 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 7599 Anagram Dr., Eden Prairie, MN 55344 (Add ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 ------------------------------ FORM 8-K ------------------------------ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): January 3, 2025 ------------------------------ FIRST INTERSTATE BANCSYSTEM, INC. (Exact name of registrant as specified in its charter) ------------------------------ | | | (State or other jurisdiction of incorporation or organization ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the quarterly period ended November 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from ______ to ______ Commission File No. 1-13146 THE GREENBRIER COMPANIES, INC. (Exact name of registrant as specified in its charter) One Centerpointe Drive, Suite 200, Lak ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Massachusetts 04-2103460 (State or Other Jurisdiction of Incorporation or Organization) 68 Jonspin Road, Wilmington, MA 01887 (Address of Principal Executive Offices) (Zip Code) (I.R.S. Employer Identification No.) Securities registered pursuant to Section 12(b) of the Act: | Title of each class | Trading Symbol | Name of each exchange on ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2025 4D Molecular Therapeutics Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39782 47-3506994 (State or Other Jurisdiction of Incorporation) 5858 HORTON STREET #455 EMERYVILLE, California 94608 (Address of Principal Executive Offices) (Zip Code) (Commissio ...

Exhibit 99.1 FOR IMMEDIATE RELEASE FRIDAY, JANUARY 10, 2025 HURCO REPORTS FOURTH QUARTER AND FULL YEAR RESULTS FOR FISCAL YEAR 2024 INDIANAPOLIS, INDIANA – January 10, 2025 – Hurco Companies, Inc. (Nasdaq: HURC) today reported results for the fourth fiscal quarter and fiscal year ended October 31, 2024. Hurco recorded a net loss of $1,442,000, or $(0.23) per diluted share, for the fourth quarter of fiscal year 2024, which included a non-cash tax valuation allowance of $193,000 recorded in provision for inco ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38166 CONCRETE PUMPING HOLDINGS, INC. (Exact name of Registrant as specified in its charter) (State or Other Jurisd ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 | Date of Report (Date of earliest event reported) January 9, 2025 | | | | --- | --- | --- | | Brookdale Senior Living Inc. | | | | (Exact name of registrant as specified in its charter) | | | | Delaware | 001-32641 | 20-3068069 | | (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | | 105 Westwood Place, Suite 400, | Brentwood, Tennessee | 37027 | | (Address of principal execu ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2025 INOZYME PHARMA, INC. (Exact name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Incorporation) 321 Summer Street Suite 400 Boston, Massachusetts 02210 (Address of Principal Executive Offices) (Zip Code) (Commission File Number) Delaware 001-39397 38- ...